Categories
Correction publisher

Publisher Correction: Oncologists greet Lumakras: the world’s first KRAS inhibitor

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-021-01053-9, published online 9 September 2021.In the version of this News article initially published, the article should have stated that in addition to Qiagen’s Therascreen, the FDA also approved Guardant360 CDx from Guardant Health, as companion diagnostics for Lumakras. In the fourth paragraph, in the third sentence beginning “It is approved…

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-021-01053-9, published online 9 September 2021.

In the version of this News article initially published, the article should have stated that in addition to Qiagen’s Therascreen, the FDA also approved Guardant360 CDx from Guardant Health, as companion diagnostics for Lumakras. In the fourth paragraph, in the third sentence beginning “It is approved for use with a companion diagnostic,” the end of the sentence has been amended to include “or Guardant360 CDx from Guardant Health.”

The online version of the article has been updated.

Author information

Affiliations

  1. Dublin, Ireland

    Cormac Sheridan

Corresponding author

Correspondence to
Cormac Sheridan.

About this article

Verify currency and authenticity via CrossMark

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *